Drug intelligence / Profile preview

FA18:4

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

FA18:4 is an omega-3 polyunsaturated fatty acid (PUFA) analogue isolated from the marine dinoflagellate *Prorocentrum lima*. It has demonstrated neuroprotective potential by modulating microglial function. Specifically, in human microglia clone 3 (HMC3) cells, FA18:4 significantly enhanced chemotactic migration and promoted amyloid-β42 (Aβ42) phagocytosis, while maintaining cellular viability and avoiding pro-inflammatory activation at a concentration of 20 μM. These findings suggest its potential therapeutic role in conditions like Alzheimer's disease.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on FA18:4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FA18:4.

Explore the full profile